In summary, signaling through the ErbB family of receptors promotes cell proliferation and opposes apoptosisand therefore must be tightly regulated to prevent uncontrolled cell growth from occurring. HER2 proteins have been shown to form clusters in cell membranes that may play a role in tumorigenesis.
Medical use[ edit ] The safety and efficacy of trastuzumab-containing combination therapies with chemotherapy, hormone blockers, or lapatinib for the treatment of metastatic breast cancer.
The overall hazard ratios for overall survival and progression free survival were 0. It was difficult to accurately ascertain the true impact of trastuzumab on survival, as in three of the seven trials, over half of the patients in the control arm were allowed to cross-over and receive trastuzumab after their cancer began to progress.
Two trials involving shorter term treatment with trastuzumab did not differ in efficacy from longer trials, but produced less cardiac toxicity. The absolute reduction in the risk of cancer returning within 3 years was 9.
However, it increases serious heart problems by an absolute risk of 2. If it is determined that a tumor is overexpressing the erbB2 oncogene and the patient has no significant pre-existing heart disease, then a patient is eligible for treatment with trastuzumab.
In fact resistance to the treatment develops rapidly, in virtually all patients. A mechanism of resistance involves failure to downregulate p27 Kip1  as well as suppressing p27 translocation to the nucleus in breast cancer, enabling cdk2 to induce cell proliferation.
One year of treatment is generally accepted based on current clinical trial evidence that demonstrated the superiority of one-year treatment over none. Debate about treatment duration has become a relevant issue for many public health policy makers because administering trastuzumab for a year is very expensive.
Consequently, some countries with a taxpayer-funded public health system, such as New Zealand, chose to fund limited adjuvant therapy. As a result, regular cardiac screening with either a MUGA scan or echocardiography is commonly undertaken during the trastuzumab treatment period.
The decline in ejection fraction appears to be reversible. These are all significant for the function and structure of cardiomyocytes.
Trastuzumab can therefore lead to cardiac dysfunction. The risk of cardiomyopathy is increased when trastuzumab is combined with anthracycline chemotherapy which itself is associated with cardiac toxicity.
Birth control[ edit ] Women having periods or whose periods stopped due to chemotherapy may need to use barrier contraception such as condoms while taking trastuzumab, and for at least six months afterwards.
This is because of the possibility of harming a developing fetus. The specific problem is: Capitalization, syntax and tone. Please help improve this section if you can. It may also upregulate cell cycle inhibitors such as p21Waf1 and p27Kip1.
In some types of cancer, the pathway is exploited to promote rapid cell growth and proliferation and hence tumor formation. Overexpression of HER2 also causes deactivation of checkpoints, allowing for even greater increases in proliferation.A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B).
INTRODUCTION AND RATIONALE 1. Anti-tumor immune response a) Evading immune response, an emerging hallmark of cancer Human tumor pathogenesis has been traditionally seen as a multistep process through which normal cells progressively acquire the capacity to transform, the so-called “hallmarks of cancer” (Hanahan et al., ) (Figure 1).
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin..
Common side effects include fever, infection. Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication.
Trastuzumab is given by slow injection into a vein and injection just under the skin.. Common side effects include fever, infection. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing.
Search Editorial board Information; List of keywords List of organizations List of authors Identifiers Full-text search: Advisory board Scientific editors.